<DOC>
	<DOCNO>NCT02496169</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy eucaLimus Sirolimus Eluting stent system patient de novo coronary lesion .</brief_summary>
	<brief_title>Prospective multicEntric NonranDomized Registry</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Subject ≥18 year minimum age require legal adult consent country enrollment . 2 . Subject acceptable candidate Percutaneous Coronary Intervention ( PCI ) . 3 . Subject acceptable candidate Emergent Coronary Artery Bypass Grafting ( CABG ) . 4 . Subject clinical evidence ischemic heart disease , stable unstable angina pectoris document silent ischemia . 5 . Subject eligible dual antiplatelet therapy treatment aspirin plus either clopidogrel , prasugrel , ticagrelor ticlopidine . 6 . Subject provide write informed consent . 7 . Subject willing comply study followup requirement . Each target lesion/vessel must meet follow angiographic criterion subject eligible trial : 1 . Subject 3 target lesion 3 separate target vessel Subject 3 target lesion 2 separate target vessel ( 2 target lesion 1 vessel 1 target lesion separate vessel ) . Subject 1 target lesion 1 vessel . 2 . Target lesion must de novo . 3 . Target lesion must major coronary artery branch ( target vessel ) . 4 . Target lesion must angiographic evidence ≥ 50 % &lt; 100 % stenosis ( operator visual estimate ) 5 . Target lesion must ≤ 35 mm length operator visual estimate . 6 . Target vessel Reference Vessel Diameter ( RVD ) 2.25mm 4.00mm operator visual estimate . 7 . Target lesion must treatable maximum 1 stent 1 . Subject clinical symptom and/or electrocardiogram ( ECG ) change consistent acute ST elevation myocardial infarction ( STEMI ) within 72 hour prior index procedure . Hemodynamically stable nonSTEMI ( NSTEMI ) subject eligible study enrollment . 2 . Subject present cardiogenic shock . 3 . Subject pregnant and/or breastfeed intend become pregnant duration study . 4 . Subject know allergy contrast medium adequately premedicated , know allergy thienopyridine , aspirin , heparin bivalirudin , L605 cobaltchromium ( CoCr ) alloy one major element ( cobalt , chromium , tungsten nickel ) , PolylacticCoGlycolic Acid ( PLGA ) , sirolimus 5 . Revascularization target vessel within 9 month prior index procedure previous PCI nontarget vessel within 30 day prior index procedure . 6 . Planned treatment lesion meeting angiographic inclusion exclusion criterion index procedure index procedure . 7 . Planned surgery within 6 month index procedure unless dual antiplatelet therapy maintain throughout perisurgical period . 8 . History stroke transient ischemic attack ( TIA ) within 6 month prior index procedure . 9 . Subjects active bleeding disorder , active coagulopathy , reason , ineligible Dual Antiplatelet Therapy ( DAPT ) . 10 . Subject refuse blood transfusion . 11 . Subject document left ventricular ejection fraction ( LVEF ) &lt; 30 % within 90 day prior index procedure . 12 . Subject dialysisdependent . 13 . Subject impaired renal function ( i.e. , blood creatinine &gt; 2.5 mg/dL 221 μmol/L determine within 7 day prior index procedure ) . 14 . Subject leukopenia ( i.e . &lt; 3,000 white blood cells/mm3 ) , thrombocytopenia ( i.e . &lt; 100,000 platelets/mm3 ) thrombocytosis ( i.e . &gt; 700,000 platelet/mm3 ) . 15 . Subject receive oral intravenous immunosuppressive therapy ( inhaled steroid permit ) , know lifelimiting immunosuppressive autoimmune disease ( e.g. , human immunodeficiency virus , systemic lupus erythematosus ; diabetes mellitus permit ) . 16 . Subject receive chronic anticoagulation ( e.g . coumadin , dabigatran , apixaban , rivaroxaban agent ) . 17 . Subject life expectancy &lt; 1 year . 18 . Subject participate another investigational ( medical device drug ) clinical study . Subjects may concurrently enrol study , long study device , drug protocol interfere investigational treatment protocol study . 19 . In investigator 's opinion , subject able comply followup requirement . Subjects exclude trial target lesions/vessels meet follow angiographic criterion : 1 . Target lesion locate within saphenous vein graft arterial graft . 2 . Target lesion involves side branch &gt; 2.0 mm diameter . Note : Lesions within 3 mm origin right coronary artery may treat . 3 . Target vessel/lesion excessively tortuous / angulate severely calcify , would prevent complete inflation angioplasty balloon . This assessment base visual estimation . 4 . Target vessel angiographic evidence thrombus . 5 . Target vessel treat brachytherapy time prior index procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>PTCA</keyword>
	<keyword>stenosis</keyword>
	<keyword>sirolimus</keyword>
	<keyword>stent</keyword>
</DOC>